Novigenix SA reported interim European validation data for its whole blood RNA signature for early detection of precancerous colorectal lesions. The data was presented in early July at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona.
Even without an oracle, it is clear that Delfi Diagnostics Inc.’s $225 million series B fundraising round positions the company well to further develop its liquid biopsy tests for early cancer detection and monitoring. Delfi’s liquid biopsy platform uses a whole genome fragmentation analysis approach for both individual cancer and multicancer detection.
C2i Genomics Inc. reported the formal launch of its C2inform minimal residual disease diagnostic across Europe, after obtaining CE marking for the cancer test. The Cambridge, Mass.-based company also has completed several clinical trials it ran with research partners to validate the technology and will be presenting data in different cancers at the American Association for Cancer Research in New Orleans, April 8-13.